Lir Life Sciences Corp. (CVE:SKNY) | Finanzwire

Basculer en Français

10247	Companies
211679	Keywords
141594	Articles
112138	Press releases

Headlines Articles Press releases Lir Life Sciences Corp.

Home
Companies
Lir Life Sciences Corp.

BRIEF

published on 04/21/2026 at 00:05, 3 hours 34 minutes ago

LIR Life Sciences Corp. Partners with Resilience BioSciences Inc.

Drug Development Preclinical Research Technology Collaboration Novel Therapies Academic Environment
PRESS RELEASE

published on 04/21/2026 at 00:00, 3 hours 39 minutes ago

LIR Life Sciences Corp. Announces Agreement with Resilience BioSciences Inc.
LIR Life Sciences Corp. announces a Technology Development Collaboration Agreement with Resilience BioSciences Inc. to enhance preclinical research activities in drug discovery and development

Drug Discovery Life Sciences Collaboration Agreement Preclinical Research Resilience BioSciences
BRIEF

published on 02/06/2026 at 00:05, 2 months 15 days ago

LIR Life Sciences Initiates Phase 2 Peptide Design with Neuland Laboratories

Transdermal Delivery LIR Life Sciences Neuland Laboratories Peptide Design Structure-Activity Relationships
PRESS RELEASE

published on 02/06/2026 at 00:00, 2 months 15 days ago

LIR Life Sciences Commences Project Phase 2 Peptide Design Program with Neuland Laboratories
LIR Life Sciences Corp. announces commencement of Project Phase 2 peptide design activities with Neuland Laboratories Limited, focusing on next-generation cell-penetrating peptides for transdermal delivery platform optimization

Transdermal Delivery Lir Life Sciences Corp. Peptide Design Project Phase 2 Neuland Laboratories Limited
BRIEF

published on 01/30/2026 at 00:05, 2 months 22 days ago

LIR Life Sciences Reports Promising Interim Preclinical Results

Transdermal Delivery Preclinical Results GLP/GIP Therapies CPP Technology Blood Glucose Control
PRESS RELEASE

published on 01/30/2026 at 00:00, 2 months 22 days ago

LIR Life Sciences Reports Positive Interim Preclinical Results from Comparative Animal Study of Novel CPP-Enabled Transdermal Delivery of GLP/GIP-Based Therapies
LIR Life Sciences Corp. announces positive interim results from a mouse study on CPP-enabled, needle-free delivery of GLP/GIP therapies, demonstrating glucose control potential

Interim Results Lir Life Sciences Corp. GLP/GIP Therapies CPP-enabled Delivery Skin-applied Formulation
BRIEF

published on 01/23/2026 at 00:05, 2 months 29 days ago

LIR Life Sciences Finalizes Study Design for Evaluating Transdermal Agents

Transdermal Delivery LIR Life Sciences Therapeutic Macromolecules Porcine Skin Model Needle-free Therapies
PRESS RELEASE

published on 01/23/2026 at 00:00, 2 months 29 days ago

LIR Life Sciences Completes Design of Ex Vivo Animal Study to Evaluate Novel Transdermal Agents for Transport of Larger Therapeutic Molecules
LIR Life Sciences Corp. announces study design for transdermal penetration of therapeutic macromolecules using ex vivo porcine skin. Focus on needle-free delivery strategies for larger therapeutics

Needle-free Delivery LIR Life Sciences Therapeutic Macromolecules Transdermal Penetration Ex Vivo Porcine Skin
BRIEF

published on 01/16/2026 at 00:05, 3 months 5 days ago

LIR Life Sciences Initiates Animal Study on Transdermal Obesity Therapies

Transdermal Delivery Obesity Therapy Animal Study LIR Life Sciences GLP/GIP-based
PRESS RELEASE

published on 01/16/2026 at 00:00, 3 months 5 days ago

LIR Life Sciences Launches Comparative Animal Study to Advance Transdermal Delivery of Second Generation GLP/GIP-based Obesity Therapies
LIR Life Sciences Corp. announces a controlled comparative animal study to evaluate needle-free transdermal delivery of GLP/GIP-based obesity therapies. Study aims to advance transdermal platform and simplify treatment for obesity

Lir Life Sciences Corp. Obesity Therapies GLP/GIP-based Controlled Study Needle-free Transdermal Delivery

Accesswire

Published on 04/21/2026 at 01:05, 2 hours 34 minutes ago

Boron One Holdings Inc. Announces Closing of Financing
Published on 04/21/2026 at 00:00, 3 hours 39 minutes ago

LIR Life Sciences Corp. Announces Agreement with Resilience BioSciences Inc.
Published on 04/20/2026 at 23:50, 3 hours 49 minutes ago

Waskahigan Oil & Gas Corp. Provides Corporate Update
Published on 04/20/2026 at 22:15, 5 hours 24 minutes ago

Jaguar Health Reports Approval of All Proposals at April 2026 Special Meeting of Stockholders
Published on 04/20/2026 at 15:25, 12 hours 14 minutes ago

Banyan Gold Announces $46.5 Million Private Placement

View all ACCESSWIRE

EQS Group

Published on 04/21/2026 at 02:05, 1 hour 34 minutes ago

Remi Preemptively Deploys Programmable Compliance Architecture, Fully Aligned with HKMA's Latest Stablecoin Licensing Standards
Published on 04/20/2026 at 22:05, 5 hours 34 minutes ago

Abivax Annual Ordinary and Extraordinary General Meeting of May 11, 2026 Availability of the Preparatory Documents
Published on 04/20/2026 at 18:59, 8 hours 39 minutes ago

EQS-Adhoc: Fabasoft AG: Fabasoft AG resolves share buyback
Published on 04/20/2026 at 18:59, 8 hours 40 minutes ago

EQS-Adhoc: Fabasoft AG: Fabasoft AG resolves share buyback
Published on 04/20/2026 at 18:45, 8 hours 54 minutes ago

Hata Completes US$8 Million Series A Financing Led by Bybit

Les Echos

Published on 04/20/2026 at 20:44, 6 hours 55 minutes ago

ENGIE - Implementation of share buyback programme
Published on 04/20/2026 at 20:01, 7 hours 38 minutes ago

TERACT - Approval by the AMF of the public buy out offer followed by a squeeze-out of TERACT shares
Published on 04/20/2026 at 17:45, 9 hours 54 minutes ago

Weekly share buyback
Published on 04/20/2026 at 17:35, 10 hours 4 minutes ago

Disclosure of transactions in own shares from April 13 to April 17, 2026
Published on 04/20/2026 at 14:00, 13 hours 39 minutes ago

Neoen awarded long-term contracts for 2 new solar farms totalling 318 MWp in Ontario, Canada

View all LES ECHOS COMFI WIRE